Flat-Price vs Dose-Scaling GLP-1 Providers, Compared

Two pricing models, one decision

Every GLP-1 telehealth program uses one of two pricing models. Learn to tell them apart before you enter a card number, because the difference decides what you actually pay over a year — not what the homepage advertises.

A **flat-price** program charges one monthly amount regardless of your dose. Month one and month twelve cost the same. A **dose-scaling** (titration-based) program ties price to how much medication you take, so your bill climbs as you move up the standard dose ladder. Both can look cheap at signup, because signup is the lowest dose. That is the trap. This guide is educational only and not medical advice.

Why dose-scaling bites during titration

GLP-1 medications are meant to be increased gradually. You start low to limit nausea, then step up over months toward a maintenance dose. That is the design of the drugs, and it is exactly where dose-scaling pricing turns against you: the same schedule that manages side effects also walks your bill upward, month after month, right when you are least able to judge whether the higher price is worth it.

The clinical results that make these drugs worth taking were measured at full maintenance doses, not the starter dose you pay the introductory price for. Semaglutide produced roughly 15% average body-weight loss in the STEP 1 trial¹, and tirzepatide reached about 20% at its higher doses in SURMOUNT-1². To get near those figures you climb the ladder — and under dose-scaling, climbing the ladder is the same act as raising your monthly cost.

A 12-month cost illustration

Numbers below are illustrative examples only — not any specific provider's pricing — to show the shape of the two curves. Confirm real figures with each program before deciding.

Say a flat program charges an illustrative $250 every month. Twelve months is a flat $3,000, and you knew that on day one.

Now a dose-scaling program that opens at an illustrative $200 but rises with each titration step: perhaps $200 for the first two months, $275 for the next three, $350 for the next three, and $425 for the final four as you reach maintenance. That path totals roughly $4,075 across the year — over a thousand dollars more than the flat option — even though its advertised starting price looked lower. The cheaper headline was the most expensive plan.

The lesson is not the exact dollars. It is that a lower starting price under dose-scaling tells you almost nothing about the twelve-month total, while a flat price tells you everything.

Maintenance means this compounds

This is not a one-year decision you make once and forget. GLP-1 benefits depend on staying on treatment. When people stopped semaglutide in the STEP 4 trial, weight came back³, and the SURMOUNT-4 trial showed the same pattern with tirzepatide — continuing treatment maintained the loss, stopping reversed it⁴. Realistically you are budgeting for many months, likely years. A pricing model that drifts upward does not just cost more this year; it compounds every year you stay on, which is the whole point of the medication.

The decisive rule

For predictability, choose flat. A single monthly number you can put in a household budget beats a lower headline that escalates precisely as the drug starts working. If two programs are otherwise comparable on clinical oversight and product sourcing, let the flat-price one win on cost certainty alone.

Run every candidate through the GLP-1 cost cheat sheet so you are comparing true monthly totals, not intro rates. For a flat-price shortlist pick, CoreAge Rx is one we point busy moms toward when predictable budgeting matters more than shaving a few dollars off month one. Confirm current pricing directly, then make the final call with a clinician who can see your whole picture.